High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients

PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma

(2018) Katrin Schaper-Gerhardt et al.   EUROPEAN JOURNAL OF CANCER

Prognostic significance of PD-L1 in solid tumor

(2017) Qianqian Wang et al.   MEDICINE

Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases

(2017) Manuel D Keller et al.   MODERN PATHOLOGY

A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma

(2016) Mashaal Dhir et al.   ANNALS OF SURGERY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Checkpoint Immunotherapy: Picking a Winner

(2016) M. W. L. Teng et al.   Cancer Discovery

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers

(2016) Marta Usó et al.   Oncotarget

PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma

(2016) Chang-Long Chen et al.   OncoImmunology

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma

(2015) Joon Hyeok Lee et al.   GASTROENTEROLOGY

Immunological landscape and immunotherapy of hepatocellular carcinoma

(2015) Jesús Prieto et al.   Nature Reviews Gastroenterology & Hepatology

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

(2015) Lars Henning Schmidt et al.   PLoS One

Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer

(2014) K. Pan et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy

(2014) Yuichiroh Umemoto et al.   JOURNAL OF GASTROENTEROLOGY

The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients

(2013) Ke Pan et al.   ANNALS OF SURGICAL ONCOLOGY

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells

(2010) Takashi Inozume et al.   JOURNAL OF IMMUNOTHERAPY

Intraepithelial T cells and tumor proliferation

(2009) Sarah F. Adams et al.   CANCER

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection

(2009) Ming Shi et al.   CLINICAL IMMUNOLOGY